Discovery and Development of Small Molecule Drugs to Enhance Patient Lives

Welcome to Rigel

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare immune diseases.


TAVALISSE (fostamatinib disodium hexahydrate) tablets are indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Our Pipeline

Rigel has a robust and growing pipeline of investigational products focused on treating disease by modulating the immune system.


Clinical Trials

Rigel is enrolling a Phase 3 clinical study of an investigational drug for warm antibody Autoimmune Hemolytic Anemia (AIHA).

read more »